The Valley Desk

NCT03763643 · Interventional trial

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Overall registry status Completed

Early Phase 1

Conditions Focal Segmental Glomerulosclerosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov